Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME of AZD1722 in Healthy Male Volunteers
NCT02063386Phase 1Completed
- Sponsor
- Ardelyx
- Start
- Apr 2014
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tenapanor in irritable bowel syndrome with constipation (IBS-C) and hyperphosphatemia, sponsored by Ardelyx. Primary endpoints: Percentage of radioactive dose recovered in urine and feces, Total percentage of radioactive dose recovered from both urine and feces and 2 more. Started Apr 2014; status: completed.
02
Drugs
tenapanor
03
Conditions
irritable bowel syndrome with constipation (IBS-C)hyperphosphatemia
Beyond the preview
Go deeper on NCT02063386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02063386.